Togaviridae Disease Overview

Save information for later
Sign Up

Learn About Togaviridae Disease

What is the definition of Togaviridae Disease?
Togaviridae disease is a term used to describe a family of viruses grouped into two categories: Alphavirus and Rubivirus. Alphaviruses are spread primarily by mosquitoes and other insects, spiders, or crustaceans to humans and cause arthritis and encephalitis. Rubivirus, commonly known as Rubella, causes the childhood disease and is transmitted through airborne aerosol droplets.
What are the symptoms of Togaviridae Disease?
Symptoms of alphaviruses can include flu-like symptoms, fever, arthritis, headache, pain, muscle pain, rash, encephalitis, and/or other further complications. Symptoms of Rubella include fever, joint pain, headache, rash, and swollen glands (lymph nodes).
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Togaviridae Disease?
Treatment for Togaviridae disease is mainly supportive care that addresses symptoms or complications. Other methods of prevention include vector-control and protecting against mosquito bites.
Who are the top Togaviridae Disease Local Doctors?
Johan Neyts
Elite in Togaviridae Disease
Johan Neyts
Elite in Togaviridae Disease
Johan Neyts

Immunology And Transplantation, VirusBank Platform, KU Leuven

Leuven, VLG, BE 

Johan Neyts practices in Leuven, Belgium. Mr. Neyts is rated as an Elite expert by MediFind in the treatment of Togaviridae Disease. His top areas of expertise are Yellow Fever, Hepatitis E, Viral Hemorrhagic Fever, Parainfluenza Virus Type 3, and Lung Transplant.

Elite in Togaviridae Disease
Annette Mankertz
Elite in Togaviridae Disease
Annette Mankertz
Berlin, BE, DE 

Annette Mankertz practices in Berlin, Germany. Ms. Mankertz is rated as an Elite expert by MediFind in the treatment of Togaviridae Disease. Her top areas of expertise are Rubella, Mumps, Togaviridae Disease, and Parainfluenza.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Togaviridae Disease
Dr. Gregory A. Poland
Internal Medicine
Elite in Togaviridae Disease
Dr. Gregory A. Poland
Internal Medicine
200 1st St Sw, 
Rochester, MN 
507-284-2511
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Gregory Poland is a primary care provider, practicing in Internal Medicine in Rochester, Minnesota. Dr. Poland is rated as an Elite provider by MediFind in the treatment of Togaviridae Disease. His top areas of expertise are Rubella, Togaviridae Disease, Smallpox, and Measles. Dr. Poland is currently accepting new patients.

View All Doctors
What are the latest Togaviridae Disease Clinical Trials?
The AEVI-Fiji Cohort Study: a Longitudinal Study Assessing the Transmission Risk and Dynamics of Mosquito-borne and Respiratory Viruses in Fiji.
The AEVI-Fiji Cohort Study: a Longitudinal Study Assessing the Transmission Risk and Dynamics of Mosquito-borne and Respiratory Viruses in Fiji.
Enrollment Status: Recruiting
Publish Date: December 01, 2025

Background: Fiji, an archipelago in the South Pacific comprising 332 islands distributed among 4 health administrative divisions (Central, Western, Eastern, Northern), is particularly vulnerable to the (re-)emergence of arboviruses and respiratory viruses due to its sub-tropical climate, the presence of several mosquito vector species, and connections with many countries in the Pacific, Asia and North America...

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Parallel Group, Phase III Randomized, Modified Double-blind, Active Controlled Study to Investigate the Immunogenicity and Safety of vYF Compared to Licensed YF Vaccines in Pediatric Population Aged 9 Months to 5 Years of Age
A Parallel Group, Phase III Randomized, Modified Double-blind, Active Controlled Study to Investigate the Immunogenicity and Safety of vYF Compared to Licensed YF Vaccines in Pediatric Population Aged 9 Months to 5 Years of Age
Enrollment Status: Recruiting
Publish Date: October 28, 2025
Intervention Type: Biological
Study Phase: Phase 3

Summary: The purpose of this study is to determine whether vYF (investigational vaccine) is safe and can help the body to develop antibodies (immunogenicity) compared with Stamaril vaccine and YF-VAX vaccine (both licensed vaccines) and when they are co-administered with Measles Mumps Rubella (MMR) vaccines in infants aged 11-15 months. Number of Participants: A total of 2440 participants is planned to be ...

View All Clinical Trials